QLT’s experimental eye drug could be worth up to $750 million

(Reuters) – Canadian eye drug developer QLT Inc expects its synthetic retinoid program, an experimental treatment for some inherited eye diseases that can cause blindness, to be valued at up to $750 million. (Source: Reuters: Health)
Source: Blindness